欧洲神经内分泌肿瘤学会SSTR-PET疗效评估框架共识别发布
欧洲神经内分泌肿瘤学会通过改良德尔菲法,组织34名国际专家经四轮评估76条声明(共识阈值≥75%一致),制定神经内分泌肿瘤生长抑素受体PET疗效评估框架SSTR-PeRForm。该框架以靶病灶体积变化为主、辅以新病灶评估,定义部分缓解为靶病灶体积缩小≥40%且无新病灶,进展为体积增大≥40%或出现新病灶,完全缓解需无病理性示踪剂摄取,并引入未确认进展类别供短期复查。
要点
- SSTR-PET疗效评估采用靶病灶体积变化为主,不依赖标准化摄取值指标
- 部分缓解:靶病灶体积缩小≥40%且无新病灶;进展:体积增大≥40%或新病灶
- 引入未确认进展类别,用于模棱两可病例的短期复查确认
核心结论
- SSTR-PeRForm框架为神经内分泌肿瘤生长抑素受体PET疗效评估提供统一标准,尚待生存结局验证。
研究设计与样本
- 欧洲神经内分泌肿瘤学会协调的结构化改良德尔菲共识,34名国际多学科专家参与四轮迭代评估76条声明,共识定义为至少75%一致。
主要发现
- 框架以表达生长抑素受体的靶病灶体积变化为主要分类依据,辅以新病灶评估,而非依赖标准化摄取值指标。
- 部分缓解定义为靶病灶体积缩小至少40%且无新病灶,进展定义为靶病灶体积增大至少40%或出现新病灶。
- 完全缓解要求无病理性示踪剂摄取,并引入未确认进展类别用于需短期复查的模棱两可病例。
关键数值与推荐
- 部分缓解:靶病灶体积缩小≥40%且无新病灶。
- 进展:靶病灶体积增大≥40%或出现新病灶。
- 完全缓解:无病理性示踪剂摄取。
- 共识阈值:至少75%专家一致。
临床怎么用
- 该框架可用于临床试验和常规实践中统一SSTR-PET疗效评估,尤其适用于以体积变化为核心的疗效判断。
局限性
- 框架尚未针对生存结局进行验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Somatostatin receptor PET imaging is integral to the management of patients with neuroendocrine tumours (NETs), yet standardised criteria for therapy response assessment with the use of this modality are not available. This Policy Review reports the development of the European Neuroendocrine Tumor Society somatostatin receptor PET response assessment framework, established through a structured modified Delphi process coordinated by the European Neuroendocrine Tumor Society. 34 international experts from nuclear medicine, radiology, oncology, endocrinology, surgery, and related disciplines participated in four iterative rounds evaluating 76 statements, with consensus defined as at least 75% agreement. The framework proposes response categorisation based primarily on volumetric changes in somatostatin receptor-expressing target lesions, complemented by assessment of new lesions, rather than reliance on standardised uptake value-based metrics. Partial response is defined by at least 40% reduction in target lesion volume without new lesions, whereas progressive disease is defined by at least 40% volume increase of target lesions or the emergence of new lesions. Complete response requires absence of pathological tracer uptake, and a category of unconfirmed progressive disease is introduced for equivocal cases warranting short-interval reassessment. Although not yet validated against survival outcomes, this expert-derived framework (SSTR-PeRForm) provides a pragmatic foundation for harmonising somatostatin receptor PET-based response assessment in clinical trials and routine practice and represents a key step towards outcome-based validation.
引用
- Deroose CM, Leupe H, Hicks RJ, et al. Somatostatin receptor PET response assessment framework for patients with neuroendocrine tumours (V1.0): a modified Delphi consensus from the European Neuroendocrine Tumor Society (endorsed by EANM and NANETS). Lancet Oncol. 2026. PMID: 42398521. doi:10.1016/S1470-2045(26)00145-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。